{"success":true,"data":{"pressRelease":{"id":"142943","rtpr_id":"nACShJB7ka-20260914","ticker":"TNON","exchange":"NASDAQ","all_tickers":["TNON"],"title":"Tenon Medical Announces Closing of Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338","author":"ACCESSWIRE","published_at":"2026-09-14T16:35:00.249Z","article_body":"LOS GATOS, CA / ACCESS Newswire (https://www.accessnewswire.com/) / September\n14, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) (\"Tenon\" or the \"Company\"), a\nmedical device company dedicated to transforming care for patients with\ncertain sacro-pelvic disorders, announced today it has closed its previously\nannounced warrant inducement agreement with an institutional investor to\nexercise outstanding warrants to purchase an aggregate of 572,179 of the\nCompany's shares of common stock (the \"Existing Warrants\").\n\nIn consideration for the immediate exercise in full of the Existing Warrants\nfor gross cash proceeds of $2,872,338.58, the exercising holder received new\nunregistered warrants (the \"New Warrants\") to purchase up to an aggregate of\n858,269 shares of common stock (equal to 150% of the shares of common stock\nissued in connection with the exercise of the Existing Warrants) with an\nexercise price of $5.02 per share. The New Warrants are immediately\nexercisable on the date of issuance and will expire five years from the date\nof issuance.\n\nThe gross proceeds from the warrant inducement were $2,872,338.58, excluding\nany proceeds that may be received upon the exercise of the New Warrants and\nbefore deducting financial advisor fees and other expenses payable by the\nCompany.\n\nWallachBeth Capital acted as financial advisor for the warrant inducement\ntransaction.\n\nThe New Warrants described above were offered in a private placement pursuant\nto an applicable exemption from the registration requirements of the\nSecurities Act of 1933, as amended (the \"Act\") and, along with the shares of\ncommon stock issuable upon their exercise, have not been registered under the\nAct, and may not be offered or sold in the United States absent registration\nwith the Securities and Exchange Commission (\"SEC\") or an applicable exemption\nfrom such registration requirements. The Company has agreed to file a\nregistration statement with the SEC covering the resale of the shares of\ncommon stock issuable upon exercise of the New Warrants (the \"Resale\nRegistration Statement\").\n\nThis press release does not constitute an offer to sell or the solicitation of\nan offer to buy, nor will there be any sales of these securities in any\njurisdiction in which such offer, solicitation or sale would be unlawful prior\nto registration or qualification under the securities laws of such\njurisdiction.\n\nAbout Tenon Medical, Inc.\n\nTenon Medical, Inc., a medical device company dedicated to transforming care\nfor patients with certain sacro-pelvic disorders. Tenon was incorporated in\nthe State of Delaware in 2012 and currently offers two systems to treat a\ndiseased sacroiliac joint (the \"SI Joint\"). The Company has developed The\nCatamaran(™) SI Joint Fusion System that offers a novel, less invasive\napproach to the SI Joint using a single, robust titanium implant. In August\n2025, the Company acquired substantially all of the assets of SiVantage, Inc.\nand SIMPL Medical, LLC, including the SImmetry+(®) SI Joint Fusion System,\nwhich treats disorders of the SI Joint through a minimally invasive lateral\naccess solution that incorporates well-established orthopedic fusion\nprinciples. Since the national launch of The Catamaran System in October 2022,\nTenon is focused on three commercial opportunities: 1) primary SI Joint\nprocedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint\nfusion adjunct to a spine fusion construct.\n\nFor more information, please visit www.tenonmed.com. Information on the\nCompany's website does not constitute a part of and is not incorporated by\nreference into this press release.\n\nThe Tenon Medical logo shown above, and Catamaran(®), PiSIF(®), CAT\nPiSIF(®), ETAD(®), Posterior Inferior Sacroiliac Fusion(®), CAT SIJ Fusion\nSystem(®), Catamaran SIJ Fusion System(®), Catamaran Inferior Posterior\nFusion System(®), Catamaran Transfixation Fusion System(®), Catamaran\nTransfixation Fusion Device(®), SImmetry(®) are registered trademarks of\nTenon Medical, Inc. MAINSAILTM, and SImmetry+(™) are also trademarks of\nTenon Medical, Inc.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking statements,\" which are statements\nrelated to events, results, activities or developments that Tenon expects,\nbelieves or anticipates will or may occur in the future. Forward-looking often\ncontains words such as \"intends,\" \"estimates,\" \"anticipates,\" \"hopes,\"\n\"projects,\" \"plans,\" \"expects,\" \"seek,\" \"believes,\" \"see,\" \"should,\" \"will,\"\n\"would,\" \"target,\" and similar expressions and the negative versions thereof.\nThese forward-looking statements, include, but are not limited to, statements\nregarding the completion of the Offering, the satisfaction of customary\nclosing conditions related to the Offering and the anticipated use of proceeds\ntherefrom. Such statements are based on Tenon's experience and perception of\ncurrent conditions, trends, expected future developments and other factors it\nbelieves are appropriate under the circumstances, and speak only as of the\ndate made. Forward-looking statements are inherently uncertain and actual\nresults may differ materially from assumptions, estimates or expectations\nreflected or contained in the forward-looking statements as a result of\nvarious factors. For details on the uncertainties that may cause Tenon's\nactual results to be materially different than those expressed in any\nforward-looking statements, please review Tenon's Annual Report on Form 10-K\nfor the fiscal year ended December 31, 2025 and updated from time to time in\nour Form 10-Q filings and in our other public filings on file with the SEC at\nwww.sec.gov statements contain, particularly the information contained in the\nsection entitled \"Risk Factors.\" We undertake no obligation to publicly update\nor revise any forward-looking statements to reflect new information or future\nevents or otherwise unless required by law.\n\nInvestor Contact\n\nShannon Devine\nMZ North America\n203-741-881\ntenon@mzgroup.us\n\nSOURCE: Tenon Medical\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/education/tenon-medical-announces-closing-of-warrant-inducement-offering-for-aggregate-gross-procee-1220583)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACShJB7ka-20260914","title":"Tenon Medical Announces Closing of Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338","author":"ACCESSWIRE","ticker":"TNON","created":"2026-09-14T16:35:00.249Z","tickers":["TNON"],"exchange":"NASDAQ","article_body":"LOS GATOS, CA / ACCESS Newswire (https://www.accessnewswire.com/) / September\n14, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) (\"Tenon\" or the \"Company\"), a\nmedical device company dedicated to transforming care for patients with\ncertain sacro-pelvic disorders, announced today it has closed its previously\nannounced warrant inducement agreement with an institutional investor to\nexercise outstanding warrants to purchase an aggregate of 572,179 of the\nCompany's shares of common stock (the \"Existing Warrants\").\n\nIn consideration for the immediate exercise in full of the Existing Warrants\nfor gross cash proceeds of $2,872,338.58, the exercising holder received new\nunregistered warrants (the \"New Warrants\") to purchase up to an aggregate of\n858,269 shares of common stock (equal to 150% of the shares of common stock\nissued in connection with the exercise of the Existing Warrants) with an\nexercise price of $5.02 per share. The New Warrants are immediately\nexercisable on the date of issuance and will expire five years from the date\nof issuance.\n\nThe gross proceeds from the warrant inducement were $2,872,338.58, excluding\nany proceeds that may be received upon the exercise of the New Warrants and\nbefore deducting financial advisor fees and other expenses payable by the\nCompany.\n\nWallachBeth Capital acted as financial advisor for the warrant inducement\ntransaction.\n\nThe New Warrants described above were offered in a private placement pursuant\nto an applicable exemption from the registration requirements of the\nSecurities Act of 1933, as amended (the \"Act\") and, along with the shares of\ncommon stock issuable upon their exercise, have not been registered under the\nAct, and may not be offered or sold in the United States absent registration\nwith the Securities and Exchange Commission (\"SEC\") or an applicable exemption\nfrom such registration requirements. The Company has agreed to file a\nregistration statement with the SEC covering the resale of the shares of\ncommon stock issuable upon exercise of the New Warrants (the \"Resale\nRegistration Statement\").\n\nThis press release does not constitute an offer to sell or the solicitation of\nan offer to buy, nor will there be any sales of these securities in any\njurisdiction in which such offer, solicitation or sale would be unlawful prior\nto registration or qualification under the securities laws of such\njurisdiction.\n\nAbout Tenon Medical, Inc.\n\nTenon Medical, Inc., a medical device company dedicated to transforming care\nfor patients with certain sacro-pelvic disorders. Tenon was incorporated in\nthe State of Delaware in 2012 and currently offers two systems to treat a\ndiseased sacroiliac joint (the \"SI Joint\"). The Company has developed The\nCatamaran(™) SI Joint Fusion System that offers a novel, less invasive\napproach to the SI Joint using a single, robust titanium implant. In August\n2025, the Company acquired substantially all of the assets of SiVantage, Inc.\nand SIMPL Medical, LLC, including the SImmetry+(®) SI Joint Fusion System,\nwhich treats disorders of the SI Joint through a minimally invasive lateral\naccess solution that incorporates well-established orthopedic fusion\nprinciples. Since the national launch of The Catamaran System in October 2022,\nTenon is focused on three commercial opportunities: 1) primary SI Joint\nprocedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint\nfusion adjunct to a spine fusion construct.\n\nFor more information, please visit www.tenonmed.com. Information on the\nCompany's website does not constitute a part of and is not incorporated by\nreference into this press release.\n\nThe Tenon Medical logo shown above, and Catamaran(®), PiSIF(®), CAT\nPiSIF(®), ETAD(®), Posterior Inferior Sacroiliac Fusion(®), CAT SIJ Fusion\nSystem(®), Catamaran SIJ Fusion System(®), Catamaran Inferior Posterior\nFusion System(®), Catamaran Transfixation Fusion System(®), Catamaran\nTransfixation Fusion Device(®), SImmetry(®) are registered trademarks of\nTenon Medical, Inc. MAINSAILTM, and SImmetry+(™) are also trademarks of\nTenon Medical, Inc.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking statements,\" which are statements\nrelated to events, results, activities or developments that Tenon expects,\nbelieves or anticipates will or may occur in the future. Forward-looking often\ncontains words such as \"intends,\" \"estimates,\" \"anticipates,\" \"hopes,\"\n\"projects,\" \"plans,\" \"expects,\" \"seek,\" \"believes,\" \"see,\" \"should,\" \"will,\"\n\"would,\" \"target,\" and similar expressions and the negative versions thereof.\nThese forward-looking statements, include, but are not limited to, statements\nregarding the completion of the Offering, the satisfaction of customary\nclosing conditions related to the Offering and the anticipated use of proceeds\ntherefrom. Such statements are based on Tenon's experience and perception of\ncurrent conditions, trends, expected future developments and other factors it\nbelieves are appropriate under the circumstances, and speak only as of the\ndate made. Forward-looking statements are inherently uncertain and actual\nresults may differ materially from assumptions, estimates or expectations\nreflected or contained in the forward-looking statements as a result of\nvarious factors. For details on the uncertainties that may cause Tenon's\nactual results to be materially different than those expressed in any\nforward-looking statements, please review Tenon's Annual Report on Form 10-K\nfor the fiscal year ended December 31, 2025 and updated from time to time in\nour Form 10-Q filings and in our other public filings on file with the SEC at\nwww.sec.gov statements contain, particularly the information contained in the\nsection entitled \"Risk Factors.\" We undertake no obligation to publicly update\nor revise any forward-looking statements to reflect new information or future\nevents or otherwise unless required by law.\n\nInvestor Contact\n\nShannon Devine\nMZ North America\n203-741-881\ntenon@mzgroup.us\n\nSOURCE: Tenon Medical\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/education/tenon-medical-announces-closing-of-warrant-inducement-offering-for-aggregate-gross-procee-1220583)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-09-14T16:35:00.296883321Z","server_sent_at_ms":1789403700296},"received_at":"2026-09-14T16:35:00.350Z","source_url":"https://www.accessnewswire.com/newsroom/en/education/tenon-medical-announces-closing-of-warrant-inducement-offering-for-aggregate-gross-procee-1220583"},"analysis":{"id":"131775","press_release_id":"142943","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["150% warrant reload coverage (858,269 shares) creates dilution overhang far larger than the 572,179 shares issued on exercise","Modest ~$2.9M gross proceeds before fees suggest ongoing cash burn and likely future capital raises","Resale registration statement for the new warrant shares will enable near-term selling pressure once effective"],"eventType":"offering","narrative":"Tenon Medical closed a previously announced warrant inducement agreement with an institutional investor, who exercised in full 572,179 existing warrants for gross cash proceeds of $2,872,338.58.\n\nAs consideration, the exercising holder received new unregistered warrants to purchase 858,269 shares — 150% of the shares issued — at a $5.02 exercise price, immediately exercisable and expiring five years from issuance.\n\nThe company agreed to file a resale registration statement with the SEC covering shares underlying the new warrants, and WallachBeth Capital acted as financial advisor on the transaction.\n\nThe structure layers a meaningful dilution overhang onto modest proceeds, a financing pattern typical of cash-constrained micro-cap medtech firms.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap warrant inducement with 150% reload warrants — small cash boost now, dilution overhang later once the resale registration goes effective."},"keyFigures":{"sharesOffered":572179,"customDimensions":{"new_warrant_term":"5 years, immediately exercisable","warrant_coverage":"150%","new_warrant_shares":858269,"new_warrant_exercise_price":5.02}},"namedEntities":{"people":[{"name":"Shannon Devine","role":"Investor Contact, MZ North America"}],"products":["The Catamaran SI Joint Fusion System","SImmetry SI Joint Fusion System"],"companies":[{"name":"Tenon Medical, Inc.","ticker":"TNON","relationship":"filer"},{"name":"WallachBeth Capital","relationship":"financial advisor"},{"name":"SiVantage, Inc.","relationship":"acquired assets (August 2025)"},{"name":"SIMPL Medical, LLC","relationship":"acquired assets (August 2025)"},{"name":"MZ North America","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$2,872,338.58","context":"gross proceeds from warrant inducement"},{"amount":"$5.02","context":"exercise price of new warrants"}]},"materialImpact":{"score":3,"reasoning":"Dilutive warrant inducement: the holder exercised 572,179 warrants for only ~$2.87M gross while receiving new warrants for 858,269 shares (150% coverage) as a sweetener, creating a dilution overhang that is large relative to proceeds for a micro-cap. Not market-moving, but a real capital-structure event for TNON holders."},"tickerRelevance":{"others":[],"primary":"TNON"},"globalImportance":12,"audienceRelevance":10,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"small dilutive warrant inducement","financingSize":"~$2.9M gross proceeds","issuerAuthored":true,"dilutionStructure":"150% warrant coverage reload"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":3,"narrative":"Tenon Medical closed a previously announced warrant inducement agreement with an institutional investor, who exercised in full 572,179 existing warrants for gross cash proceeds of $2,872,338.58.\n\nAs consideration, the exercising holder received new unregistered warrants to purchase 858,269 shares — 150% of the shares issued — at a $5.02 exercise price, immediately exercisable and expiring five years from issuance.\n\nThe company agreed to file a resale registration statement with the SEC covering shares underlying the new warrants, and WallachBeth Capital acted as financial advisor on the transaction.\n\nThe structure layers a meaningful dilution overhang onto modest proceeds, a financing pattern typical of cash-constrained micro-cap medtech firms.","key_figures":{"sharesOffered":572179,"customDimensions":{"new_warrant_term":"5 years, immediately exercisable","warrant_coverage":"150%","new_warrant_shares":858269,"new_warrant_exercise_price":5.02}},"named_entities":{"people":[{"name":"Shannon Devine","role":"Investor Contact, MZ North America"}],"products":["The Catamaran SI Joint Fusion System","SImmetry SI Joint Fusion System"],"companies":[{"name":"Tenon Medical, Inc.","ticker":"TNON","relationship":"filer"},{"name":"WallachBeth Capital","relationship":"financial advisor"},{"name":"SiVantage, Inc.","relationship":"acquired assets (August 2025)"},{"name":"SIMPL Medical, LLC","relationship":"acquired assets (August 2025)"},{"name":"MZ North America","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$2,872,338.58","context":"gross proceeds from warrant inducement"},{"amount":"$5.02","context":"exercise price of new warrants"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-14T16:35:36.298Z","global_importance":12,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"small dilutive warrant inducement","financingSize":"~$2.9M gross proceeds","issuerAuthored":true,"dilutionStructure":"150% warrant coverage reload"}},"durationMs":35934,"modelName":"glm-5.3-flash"}}